medigraphic.com
Academia Mexicana de Neurología, A.C.

2005, Número 1

<< Anterior Siguiente >>

Rev Mex Neuroci 2005; 6 (1)


Nuevos factores de riesgo en la enfermedad cerebrovascular isquémica

Vera AH, Vera CH

Idioma: Español
Referencias bibliográficas: 92
Paginas: 68-77
Archivo PDF: 111.98 Kb.


RESUMEN

Se hace una revisión de nuevos factores de riesgo en la enfermedad cerebrovascular isquémica. Se precisan los criterios sustentados en la década de los 90 y se presentan algunos de estos nuevos factores que han sido menos investigados: estatura, índice de masa corporal, anticuerpos antifosfolípidos y lipoproteína (a). Se concluye con las valoraciones sobre tres que han recibido más atención de los investigadores: infección e inflamación, homocisteína y la genética en general.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Programa Nacional de Prevención y Control de las Enfermedades Cerebrovasculares. Ministerio de Salud Pública. República de Cuba. Junio del 2000.

  2. Elkind MS, Sacco RL. Stroke risk factors and stroke prevention. Semin-Neurol 1998; 18(4): 429-40.

  3. Greenwood R, McCarron P, Elwood P, Sklomo YB, Bayer A, Baker I, et al. The incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies I: methods and incidence of events. Public Health 2001; 115(1): 4-11.

  4. Sacco RL. Identifying patient populations at high risk for stroke. Neurology 1998; 51(3 Suppl 3): 527-30.

  5. McCarron P, Greenwood R, Elwood P, Shlomo YB, Bayer A, Baker I, et al. The incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies II: risk factors for ischaemic stroke. Public Health 2001; 115(1): 12-20.

  6. Special Report From the National Institute of Neurological Disorders and Stroke. Stroke 1990; 21(4): 637-76.

  7. Report of WHO Task-Force on Stroke and other Cerebrovascular disorders. Stroke 1989; 20(10): 1407-37.

  8. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone AL, Rader D, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999; 281(12): 1112-20.

  9. Parker DR, Lapane KL, Lasater TM, Carleton RA. Short stature and cardiovascular disease among men and women from two southeastern New England communities. Int J Epidemiol 1998; 27(6): 970-5.

  10. Wannamethee SG, Shaper AG, Whincup PH, Walker M. Adult height, stroke, and coronary heart disease. Am J Epidemiol 1998; 148(11): 1069-76.

  11. Hart CL, Hole DJ, Smith GD. Comparison of risk factor for stroke incidence and stroke mortality in 20 years of follow-up in men and women in the Renfrew/Paisley Study in Scotland. Stroke 2000; 31(8): 1893-6.

  12. Goldbourt U, Tanne D. Body height is associated with decreased long-term stroke but coronary heart disease mortality? Stroke 2002; 33(3): 743-8.

  13. Feigin VL, Wiebers DO, Nikitin YP, O’Fallon WM, Whisnant JP. Risk factors for ischemic in a Russian community: a population-based case-control study. Stroke 1998; 29(1): 34.9.

  14. Woo J, Ho SC, Yuen YK, Lau J. Cardiovascular risk factors and 18-month mortality and morbidity in an elderly Chinese population aged 70 years and over. Gerontology 1998; 44(1): 51-5.

  15. Zhuo BF. Effect of body mass index on all-cause mortality and incidence cardiovascular diseases-report for meta-analysis of prospective studies open optimal cut-off points of body mass index in Chinese adults. Biomed Environ Sci 2002; 15(3): 245-52.

  16. Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, Cook NR, et al. Body mass index and the risk of stroke in men. Arch Intern Med 2002; 162(22): 2557-62.

  17. Dey DK, Rothenberg E, Sundh V, Bosaeus I, Steen B. Waist circumference, body mass index, and risk for stroke in older people: a 15 year longitudinal population study of 70-year-olds. J Am Geriatr Soc 2002; 50(9); 151.

  18. Brey RL, Stallworth CL, McGlasson DL, Wozniak MA, Wityk RJ, Stern BJ, et al. Antiphospholipid antibodies and stroke in young women. Stroke 2002; 33(10): 2396-400.

  19. Verro P, Levine SR, Tietjen GE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke 1998; 29(11): 2245-53.

  20. Daif AK. Anticardiolipin antibodies as an independent risk factor for stroke in young Saudis. Funct Neurol 1998; 13(4): 285-9.

  21. Ahmed E, Stegmayr B, Trifumovic J, Weinehall L, Hallmans G, Lefvert AK. Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Vasterbotten cohort projet. Stroke 2000; 31(6): 1289-93.

  22. Jung F, Miesbach W, Scharrer I. Cardiac and cerebral manifestations of antiphospholipid syndrome. Z Kardiol 2002; 91(8): 650-8.

  23. Caso V, Parnetti L, Panarelli P, Magni MP, Gallai V, Albi E. Selction of thrombogenetic antiphospholipid antibodies in cerebrovascular disease patients. J Neurol 2003; 250(5):593-7

  24. De La Pena-Díaz A, Cardoso-Saldana G, Zamora-Gonzales J, Barinagarrementeria F, Izaguirre R, Loyau S, et al. Functional approach to investigate Lp(a) in ischaemic Herat and cerebral diseases. Eur J Clin Invest 2003; 33(2): 99-105.

  25. Pantoni L, Sarti C, Pracucci G, Di Carlo A, Vanni P, Inzitari D. Lipoprotein(a) serum levels and vascular diseases in an older Caucasian population cohort. Italian Longitudinal Study on Aging (ILSA). J am Geriatr Soc 2001; 49(2): 117-25.

  26. Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein(a) and Stroke. J Clin Pathol 2000; 53(7): 487-96.

  27. Emsley HC, Tyrrell PJ. Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab 2002; 22(12): 1399-419.

  28. Kiechl S, Werner P, Egger G, Oberhollenzer F, Ma M, Xu Q, et al. Active and passive smoking, chronic infection and the risk of carotid atherosclerosis: prospective results from the Bruneck Study. Stroke 2002; 33(9): 2170-6.

  29. Fruchart JC, Duriez P. Donnée fondamentale sur atherosclerosis. Ann Endocrinol (Paris) 2001; 62(1pt2): 93-100.

  30. Magyar MT, Szikszai Z, Balla J, Valikovics A, Kappelmayer J, Imre S, et al. Early-onset carotid atherosclerosis is associated with increased intima-media thicknessand elevated serum levels of inflammatory markers. Stroke 2003; 34(1): 58-63.

  31. Tanne D, Haim M, Boyko V, Goldbourt U, Reshef T, Matetzky S, et al. Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort. Stroke 2002; 33(9): 2141-3.

  32. Paganini-Hill A, Lozano E, Fischberg G, Perez Barreto M, Rajamani K, Ameriso SF, et al. Infection and risk of ischemic stroke: differences among stroke subtypes. Stroke 2003; 34(2): 452-7.

  33. Becher H, Grau A, Steindorf K, Buggle F, Hacke W. Previous infection and other risk factors for acute verebrovascular ischaemia: attributable risks and the characterization of high risk groups. J Epidemiol Biostat 2000; 5(5): 277-83.

  34. Lichy C, Meiser H, Grond-Ginsbach C, Buggle F, Dorfer C, Grau A. Lipopolysaccharide receptor CD14 polymorphism and risk of stroke in a South-German population. J Neurol 2002; 249(7): 821-3.

  35. Revilla M, Obach V, Cervera A, Dávalos A, Castillo J, Chamorro A. A-174G/G polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci Lett 2002; 324(1): 29-32.

  36. Di Napoli M, Papa F, Bocola V. C-Reactive Protein in ischemic stroke an independent prognostic factor. Sroke 2001; 32(4): 917-24.

  37. Winbeck K, Popper H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002; 33(10): 2459-64.

  38. Engstrom G, Stavenow L, Hedblad B, Lind P, Eriksson KF, Janzon L, et al. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population based study. Diabetes 2003; 52(2): 442-7.

  39. 39. Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation 2003; 108(2): 166-70.

  40. Peng DQ, Zhao SP, Li YF, Li J, Zhou HN. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin Chim Acta 2002; 319(1): 19-26.

  41. Blake GJ, Ostfeld RJ, Yucel EK, Varo N, Schombect U, Blake MA, et al. Soluble CD40 ligand levels in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol 2003; 23(1): 11-4.

  42. DeGraba TJ, Siren AL, Penix L, McCarron RM, Hargraves R, Sood S, et al. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke 1998; 29(7): 1405-10.

  43. Mocco J, Choudhri TF, Mack WJ, Laufer I, Lee J, Kiss S, et al. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis.. Neurosurgery 2001; 48(4): 718-21.

  44. Beaudeux JL, Bure L, Imbert-Bismut F, Giral P, Bernard M, Bruckert E, et al. Serum plasma pregnancy- associated protein a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol 2003; 23(1): 7-10.

  45. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348(2): 138-50.

  46. Grau AJ, Buggle F, Becher H, Zimmermann E, Spiel M, Fent T, et al. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies. Neurology 1998; 50(1): 196-203.

  47. Joshipura KJ, Hung HC, Rimm EB, Willet WC, Ascherio A. Periodontal disease, tooth loss, and incidence of ischemic strke. Stroke 2003; 34(1): 47-52.

  48. 48. Mastragelopulos N, Haraszthy VI, Zambon JJ, Zafiropoulos GG. Detection of periodontal pathogenic microorganisms in atheromatous plaque. Preliminary results. Chirurg 2002; 73(6): 585-91.

  49. Cook PJ, Honeybourne D, Lip GY, Beevers DG, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project. Stroke 1998; 29(2): 404-10.

  50. Elkind MS, Lin IF, Grayston JT, Sacco Rl. Chlamydia pnuemoniae and the risk of first ischemic stroke: The Northern Manhattan Stroke Study. Stroke 2000; 31(7): 1521-5.

  51. Madre JG, García JL, Gonzáles RC, Montero JM, Paniagua EB, Escribano JR, et al. Association between seropositivity to Chlamydia pneumoniae acute ischaemic stroke. Eur J Neurol 2002; 9(3): 303-6.

  52. Tarnacka B, Gromadzka G, Czlonkowska A. Increased circulating immune complexes in acute stroke: the triggering role of Chlamydia pneumoniae and cytomegalovirus. Stroke 2002; 33(4): 936-40.

  53. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation 2002; 106(19): 2428-33.

  54. Ngeh J, Gupta S, Goodbourn C, Panayiotou B, McElligott G. Chlamydia pneumoniae in elderly patients with stroke (C-PEPS): a case-control study on the seroprevalence of Chlamydia pneumoniae in elderly patients with acute cerebrovascular disease. Cerebrovasc Dis 2003; 15(1-2): 11-6.

  55. Ponzetto A, Marchet A, Pellicano R, Lovera N, Chianale G, Nobili M, et al. Association of Helicobacter pylori infection with ischemic stroke of non-cardiac origen: the BAT.MA.N. project study. Hepatogastroenterology 2002; 49(45): 631-4.

  56. Moayyedi P, Carter AM, Braunholtz D, Catto AJ. Helicobacter pylori infection in subjects with acute ischaemic stroke. Dig Liver Dis 2003; 35(1): 16-9.

  57. Aronow WS, Ahn C, Gutstein H. Increased plasma homocysteine an independent predictor of new atherothrombotic brain infarction in older person. Am J Cardiol 2000; 86(5): 585-6.

  58. Meiklejonhn DJ, Vickers MA, Dejkdeusen R, Greaves M. Plasma homocisteine concentration in acute and convalescent period of atherothrombotic strke. Stroke 2001; 32(5): 57-62.

  59. Fallon VB, Elwood P, Ben Sholomo Y, Ubbink JB, Greenwood R, Smith GD. Homocisteine and ischemic stroke in men: the Caephilty Study. J epidemiol Commun Health 2001; 55(2): 91-6.

  60. Nankey GL, Eikelboom JW. Homocisteine and stroke. Curr Opin Neurol 2001; 14(1): 95-102.

  61. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Total homocysteine concentration and the likelihood of nonfatal stroke: results from the third national health and nutrition examination survey, 1988-1994. Stroke 1998; 29(12): 2473-7.

  62. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, et al. Homocysteine and short-term risk of myocardial infartion and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1998; 159(19): 38-44

  63. Spencer JD, Malinow MR, Barnett PA, Marian AJ, Freeman D, Hegele RA, et al. Plasma homocysteine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area. Stroke 1999; 30(5): 969-73.

  64. Kristensen B, Malm J, Nilsson TK, Hultdin J, Carlberg B, Dahlen G, et al. Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke. Stroke 1999; 30(5): 974-80.

  65. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999; 281(19): 1817-21.

  66. Sasaki T, Watanabe M, Nagai Y, Hoshi T, Takasawa M, Nukata M, et al. Association of plasma homocysteine concentration with atherosclerotic carotid plaques and lacunar infarction. Stroke 2002; 33(6): 1493-6.

  67. Andersson A, Hutilberg B, Lendgreen A. Redox status of plasma homocysteine and other plasma thioles in stroke patients. Atherosclerosis 2000; 151(2): 535-9.

  68. Gale CR, Ashurst H, Phillips NJ, Moat SJ, Bonham JR, Martyn CN. Renal function, plasma homocysteine and carotid atherosclerosis in erderly people. Atherosclerosis 2001; 154(1): 141-6.

  69. Huang Y, Zhao YI, Li S. Hyperhomocysteine, methilenetetrahydrofolate reductase gene, and other risk factors in ischemic stroke. Zhonghua Yi Xue Za Zhi 2002; 82(2): 119-22.

  70. Bushnel CD, Goldstein LB. Homocysteine testing in patients with acute ischemic stroke. Neurology 2002; 59(10): 1541-6.

  71. Madonna P, de Stefano V, Coppola A, Cirillo F, Cerbone AM, Orefio G, et al. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 2002; 33(6): 51.6.

  72. Tanne D, Haim M, Goldbourt U, Boyko V, Doolman R, Adler Y, et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 2003; 34(3): 632-6.

  73. El Kassi MM, Zakhry MM. Oxidative stress in the contex of acute cerebrovascular stroke. Stroke 2000; 31(8): 1889-92.

  74. Spence JD, Howard W, Chambless LE, Malinow MR, Petigrew LC, Stampfell M, et al. Vitamin intervention for stroke prevention trial: rationale and desing. Neuroepidemiology 2001; 20(1): 16-25.

  75. van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial disfunction. Semin Thromb Hemost 2000; 26(3): 281-9.

  76. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: metaanalysis. JAMA 2002; 288(16): 2015-22.

  77. Vera CH. La enfermedad cerebrovascular: aspectos clínicos y epidemiológicos. Tesis de grado para Especialista de Medicina General Integral. La Habana 1999.

  78. Hassan A, Markus HS. Genetic and ischaemic stroke. Brain 2000; 123(Pte9): 1788-812.

  79. Meshia JF. Addressing the heterogenetty of the ischemic stroke phenotype in human genetics research. Stroke 2002; 33(12): 2770-4.

  80. Starr J, Rush M, De Mey R, Dennis M, Parental cause of death in stroke. Cerebrovasc Dis 2001; 11(1): 65-70.

  81. Venti M, Parnetti L, Gallai V. Genetics of ischemic stroke. Clin Exp Hypertens 2002; 24(7-8): 531-4.

  82. Szolnoki Z, Somogyvari F, Kondacs A, Szabo M, Fodor I. Evaluation of the interactions of common genetic mutations in stroke subtypes. J Neurol 2002; 249(10): 1391-7.

  83. Jerrard-Dunne P, Markus HS, Steckel DA, Buehler A, von Kegler S, Sitzer M. Early carotid atherosclerosis and family history of vascular disease: specific effects on arterial sites have implications for genetic studies. Arterioscler Thromb Vasc Biol. 2003; 23(2): 302-6.

  84. Grossmann R, Geisen U, Merati G, Mullges W, Schambeck CM, Walter U, et al. Genetic risk factors in young adults with “cryptogenic” ischemic cerebrovascular disease. Blood Coagul Fibrinolysis. 2002; 13(7): 583-90.

  85. Li C, Zhang C, Qiu S, Lu X, Zeng Y, Wu H, et al. Polymorphisms of ACE-1 and MTHFR genes and genetic susceptibility of ischemic stroke. Zhonghua Yi Xue Za Zhi 2002; 82(15): 1046-9.

  86. Meiklejohn DJ, Vickers MA, Morrison ER, Dijkhuisen R, Moore I, Urbaniak SJ, et al. Br J Haematol. 2001; 112(3):621-31

  87. González-Conejero R, Lozano ML, Rivera J, Iniesta JA, Moraleda JM, et al. Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood 1998; 92(8): 2771-6.

  88. Kolovou GD, Daskalova DCh, Hatzivassiliou M, Yiannakouris N, Pilatis ND, Elisaf ND, et al. The epsilon 2 and 4 alleles of apolipoprotein E and ischemic vascular events in the Greek population-implications for the interpretation of similar studies. Angiology 2003; 54(1): 51-8.

  89. Hassan A, Ali N, Dong Y, Carter ND, Markus HS. Atrial natriuretic peptide gene G664A polymorphism and the risk of ischemic cerebrovascular disease. Neurology 2001; 57(9): 1726-8.

  90. Reiner AP, Kiemar PN, Schwartz SM, Longstreth WT Jr, Pearce RM, Rosendal FR, et al. Genetic variants of platelet glycoprotein receptors and risk stroke in young women. Stroke. 2000; 31(7): 1628-33.

  91. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modular vascular risk. Lancet. 2003; 361(9367): 1424-31.

  92. Gálvez Vargas R y Rodríguez-Contreras Pelayo R. Teoría de la causalidad en epidemiología. En: Piedrola Gil G. Medicina Preventiva y Salud Pública. 8va. Ed. Barcelona: Salvat; 1990.




2020     |     www.medigraphic.com